西安交通大学学报（医学版）2026，Vol.47Issue(1)：18-24,7.DOI:10.7652/jdyxb202601003
阿尔茨海默病Aβ免疫治疗的临床获益
Clinical benefits of Aβ immunotherapy for Alzheimer's disease
摘要
Abstract
The deposition of β-amyloid(Aβ)in the brain is a key step in the pathogenesis of Alzheimer's disease(AD).The clearance of Aβ using anti-Aβ monoclonal antibodies is the most important disease modification therapy(DMT)for AD.Lecanemab and Donanemab are currently two approved anti-Aβ antibodies.This article systematically reviews the results of phase Ⅲ clinical trials for these two drugs,with a particular focus on the changes in biomarkers(amyloid PET-CT and cerebrospinal fluid or plasma biomarkers)during treatment,as well as efficacy evaluation.It summarizes the heterogeneity of clinical efficacy among different patients and its possible influencing factors.Combined with preliminary follow-up data from real-world studies in Northwest China,the review systematically summarizes the clinical benefits of targeted Aβ monoclonal antibodies as DMT for AD.It proposes the adoption of a new concept"meaningful benefit"for evaluation,emphasizing that the goal of DMT for AD is not short-term symptom improvement,but the cumulative effect of long-term treatment.Specifically,the longer the treatment duration,the more pronounced the effect in delaying cognitive and functional decline,thereby postponing the time when patients progress to more severe stages of the disease.This provides important evidence for clinicians in treatment decision-making,efficacy evaluation,and patient management.关键词
阿尔茨海默病(AD)/β淀粉样蛋白(Aβ)/免疫治疗/淀粉样蛋白单克隆抗体/临床获益Key words
Alzheimer's disease(AD)/β-amyloid(Aβ)/immunotherapy/amyloid monoclonal antibody/clinical benefit分类
医药卫生引用本文复制引用
刘洁,刘佩杰,高玲,党亮君,魏珊,屈秋民,王瑾..阿尔茨海默病Aβ免疫治疗的临床获益[J].西安交通大学学报（医学版）,2026,47(1):18-24,7.基金项目
西安交通大学第一附属医院横向课题(No.HXIIT2024089)Supported by the Lateral Research Project of The First Affiliated Hospital of Xi'an Jiaotong University(No.HXIIT2024089) （No.HXIIT2024089）
